** India's Divi's Laboratories DIVI.NS gains 3.6% to 6,698 rupees
** Stock top pct gainer on pharma index .NIPHARM, which is trading 0.7% higher
** India's top API maker by capacity says it signed a long-term supply agreement with a global pharma company for supply of advanced intermediates, without naming the co
** Cost of capacity addition under deal expected to be between 6.50 bln rupees and 7.50 bln rupees ($76 mln and $88 mln) - DIVI
** DIVI says it expects "meaningful" revenue contribution from the deal
** Morgan Stanley analysts estimate "incremental revenue" of 16.90 bln rupees to 18.90 bln rupees after the deal
** DIVI top pct gainer on pharma index YTD, climbing 9.9%, vs NIPHARM's 8% decline
($1 = 85.0550 Indian rupees)
(Reporting by Kashish Tandon in Bengaluru)
((Kashish.tandon@thomsonreuters.com))